Helix BioPharma Corp. has appointed Dr. Thomas Mehrling as its new Chief Executive Officer, marking a significant leadership transition for the clinical-stage oncology company. Dr. Mehrling, who previously served as the company's Chief Medical Officer, brings over two decades of pharmaceutical oncology experience to the role.
With a distinguished background that includes leadership positions at Mundipharma International Ltd. and founding Laevoroc Medical AG, Dr. Mehrling has a proven track record of developing and bringing transformative cancer therapies to market. His appointment signals the company's commitment to advancing its clinical development strategy, particularly for its lead candidate L-DOS47.
The company plans to enter L-DOS47 into a Phase II study this year, targeting non-small cell lung cancer in combination with pembrolizumab. Dr. Mehrling emphasized the company's dedication to addressing urgent cancer challenges through innovative approaches and rapid decision-making.
Outgoing CEO Jacek Antas will continue to serve as Chairman, supporting the leadership transition and focusing on building an agile organizational structure. The leadership change comes as Helix BioPharma prepares to close a financing deal that will enable further execution of its clinical development roadmap.
Dr. Mehrling's expertise in hemato-oncology and pharmacology, combined with his experience in developing global oncology businesses, positions Helix BioPharma to potentially accelerate its pipeline of bio-conjugate therapies targeting CEACAM6-expressing solid tumors.
